Comparative efficacy & safety of buparlisib plus fulvestrant, fulvestrant plus dalpiciclib, and ribociclib plus letrozole for postmenopausal, hormone receptor-positive, and HER2-negative breast cancer

OBJECTIVES: This study aimed to compare progression-free survival, overall survival, clinical benefits, and adverse effects in postmenopausal women with hormone receptor-positive and HER2-negative breast cancer who received buparlisib plus fulvestrant against those of women who received dalpiciclib...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qi, Hou, Lingli, Zhao, Ying, Yang, Hongwei, Mo, Zhengying, Yu, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630103/
http://dx.doi.org/10.1016/j.clinsp.2023.100291

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630103/
http://dx.doi.org/10.1016/j.clinsp.2023.100291

Ejemplares similares